It destroys the DNA of microorganisms and anaerobic bacteria cells through the reduction of 5-nitroimidazole, and has strong selective toxicity to Trichomonas protozoa and anaerobic microorganisms.

The antibacterial spectrum is similar to that of rifampicin. It has good antibacterial activity against tuberculosis and leprosy. When the dosage is 1/3 of that of rifampicin, similar or higher efficacy can be achieved. It has a good effect on Staphylococcus aureus and has certain antibacterial activity against some Escherichia coli. In addition, it also has an inhibitory effect on Chlamydia trachomatis.

This product is a quinolone antibacterial drug, which has antibacterial effects on Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Serratia, Salmonella typhi, Shigella, Pseudomonas aeruginosa, etc. This product acts on bacterial DNA gyrase, interfering with the synthesis of bacterial DNA, thereby causing bacterial death.

This product is a prodrug of acyclovir. It is rapidly absorbed after oral administration and quickly converted into acyclovir in the body. Its antiviral effect is exerted by acyclovir. After acyclovir enters the herpes infected cells, it competes with deoxynucleoside for viral thymidine kinase or cellular kinase. The drug is phosphorylated into activated acyclosine triphosphate, which competes with deoxyguanine triphosphate for viral DNA polymerase as a substrate for viral replication, thereby inhibiting viral DNA synthesis and showing antiviral effect. The antiviral activity of this product in vivo is better than that of acyclovir, and the therapeutic index for herpes simplex virus type I and type II is 42.91% and 30.13% higher than that of acyclovir, respectively. It also has a high efficacy against varicella zoster virus and has very low toxicity to mammalian host cells.